Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 145.20B | 138.46B | 131.24B | 110.95B | 101.77B |
Gross Profit | 39.53B | 37.10B | 33.27B | 32.66B | 28.62B |
EBITDA | 17.91B | 16.08B | 13.97B | 16.21B | 10.68B |
Net Income | 8.41B | 7.99B | 6.95B | 11.69B | 3.37B |
Balance Sheet | |||||
Total Assets | 225.10B | 224.32B | 201.91B | 185.76B | 180.02B |
Cash, Cash Equivalents and Short-Term Investments | 24.95B | 19.98B | 17.66B | 27.07B | 25.94B |
Total Debt | 68.94B | 66.91B | 52.92B | 46.83B | 56.58B |
Total Liabilities | 110.65B | 118.21B | 104.48B | 93.89B | 100.51B |
Stockholders Equity | 114.27B | 106.07B | 97.43B | 91.87B | 79.52B |
Cash Flow | |||||
Free Cash Flow | 8.53B | -10.35B | -10.64B | 12.02B | -1.40B |
Operating Cash Flow | 18.33B | -2.81B | -6.02B | 16.50B | 4.75B |
Investing Cash Flow | -11.41B | -7.04B | -5.02B | -4.32B | -6.16B |
Financing Cash Flow | -2.34B | 11.52B | 1.05B | -11.60B | 6.36B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | ¥54.34B | 11.79 | 3.28% | 8.13% | 5.35% | ||
79 Outperform | ¥65.45B | 5.55 | 3.44% | 3.55% | 214.69% | ||
74 Outperform | ¥96.17B | 8.96 | 3.52% | 8.46% | 74.58% | ||
70 Outperform | ¥98.79B | 18.44 | 1.16% | 96.61% | 133.90% | ||
69 Neutral | ¥63.25B | 13.52 | 4.37% | 0.32% | -43.10% | ||
44 Neutral | AU$1.54B | -7.28 | -22.76% | 4.37% | -3.13% | -36.41% |
Ishihara Sangyo Kaisha, Ltd. announced the disposal of treasury stock as part of a Restricted Stock Incentive Plan for its Employee Shareholding Association. This initiative aims to enhance employee welfare, encourage asset building, and align employee and shareholder interests, with minimal market impact expected.
Ishihara Sangyo Kaisha, Ltd. has announced the implementation of a stock compensation plan for its Directors and Executive Officers, excluding Outside Directors, as well as for some of its subsidiaries’ officers. This plan, approved at the company’s 102nd Ordinary General Meeting of Shareholders, involves the acquisition of 443,800 shares of common stock through the disposal of treasury stock, with a total fund allocation of 997,218,600 yen. The initiative reflects the company’s commitment to aligning the interests of its executives with those of its shareholders, potentially impacting its operational and strategic direction.
Ishihara Sangyo Kaisha, Ltd. has announced the disposal of 443,800 shares of its treasury stock as part of a newly introduced stock compensation plan. This initiative is designed to align the interests of its directors and executive officers with shareholders by linking their remuneration to the company’s stock performance, thereby aiming to improve long-term business performance and corporate value. The disposal is expected to have minimal market impact due to its reasonable scale.
Ishihara Sangyo Kaisha, Ltd. has revised its consolidated earnings forecast for the first half of the fiscal year ending March 31, 2026, due to strong performance in insecticide sales in Europe and favorable currency exchange rates. The company expects net income to exceed previous forecasts due to lower tax expenses, although it maintains its full-year forecast due to an uncertain business environment.
Ishihara Sangyo Kaisha, Ltd. reported a strong financial performance for the first quarter of the fiscal year ending March 31, 2026, with significant increases in net sales and profits compared to the previous year. The company also included ISK Biosciences India Pvt. Ltd. in its consolidation scope, indicating an expansion in its operational footprint.
Ishihara Sangyo Kaisha, Ltd. has announced the introduction of a performance-linked stock compensation plan, known as the RS Trust, for its directors. This plan aims to align directors’ interests with company performance and shareholder value by linking compensation to stock performance, encouraging long-term corporate value improvement. The plan is subject to shareholder approval and may extend to executive officers and subsidiaries, potentially impacting the company’s governance and stakeholder relations.